BBOT officer reports tax-withheld RSU shares

BridgeBio Oncology Therapeutics, Inc. principal accounting officer Marc Cobo reported a routine tax-related share disposition.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. principal accounting officer Marc Cobo reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 125 shares of Common Stock to cover his tax obligations, rather than selling them in the open market. Following this withholding, Cobo directly holds 5,306 shares of Common Stock.

Insider Trade Summary

Exercise Price or Tax Liability: 125 shares

Exercise Price or Tax Liability 1 txn

Insider Cobo Marc

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	125	$7.80	$975.00

Holdings After Transaction: Common Stock — 5,306 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Key Figures

Tax-withheld shares: 125 shares Price per share for withholding: $7.80 per share Shares held after transaction: 5,306 shares

3 metrics

Tax-withheld shares 125 shares Common Stock withheld to cover RSU tax obligations

Price per share for withholding $7.80 per share Value used for tax-withholding disposition

Shares held after transaction 5,306 shares Direct Common Stock holdings following tax withholding

Key Terms

restricted stock units, tax withholding obligations, Common Stock, Form 4

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

Common Stock financial

"shares of the Issuer's Common Stock withheld by the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"insider Form 4 data describing the reported transaction"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Oncology Therapeutics (BBOT) insider Marc Cobo report on this Form 4?

Marc Cobo reported that 125 shares of Common Stock were withheld to cover tax obligations from vesting restricted stock units. This is a mechanical tax-withholding event, not an open-market trade, and reflects standard handling of equity compensation.

Was the BBOT Form 4 transaction by Marc Cobo an open-market stock sale?

No, the transaction was not an open-market sale. The company withheld 125 shares of Common Stock to satisfy Cobo’s tax withholding obligations on RSU vesting, according to the footnote, which describes a non-discretionary tax payment mechanism.

How many BridgeBio Oncology Therapeutics (BBOT) shares does Marc Cobo hold after this transaction?

After the tax-withholding disposition, Marc Cobo directly holds 5,306 shares of BridgeBio Oncology Therapeutics Common Stock. This figure reflects his position immediately following the withholding of 125 shares to satisfy tax obligations on vested restricted stock units.

What does transaction code "F" mean in Marc Cobo’s BBOT Form 4 filing?

Transaction code "F" indicates shares were used to pay an exercise price or tax liability. Here, 125 Common Stock shares were withheld by the issuer to cover Cobo’s tax withholding obligations when his restricted stock units vested, rather than being sold on the market.

What role does insider Marc Cobo hold at BridgeBio Oncology Therapeutics (BBOT)?

Marc Cobo is identified as an officer of BridgeBio Oncology Therapeutics with the title Principal Accounting Officer. His Form 4 filing reports a tax-withholding share disposition related to RSU vesting, not a discretionary purchase or sale of company stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cobo Marc

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		F		125(1)	D	$7.8	5,306	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Aaron Chan, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)